Intent to Sole Source - Untargeted Metabolomics Analysis
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation NOI-OLAO-CC-26-008751 in this department, oldest first.
- Aug 21, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Metabolon, Inc. Acquisition Description: The TBHP Branch (TBHP) requests the purchase of a contract for Metabolon, Inc., to perform untargeted metabolomics analysis of human fecal samples. The materials will be used in a collaborative protocol between the NIH Clinical Center TBHP Branch, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Heart, Lung,… (show all)
and Blood Institute to quantify and compare microbiome-derived metabolites and dietary xenobiotics in diets primarily consisting of unprocessed and ultra-processed food to investigate metabolic pathways altered by ultra-processed diets. The metabolomics analysis needs to be able to: Detect and quantify a broad panel of small-molecule metabolites (including dietary xenobiotics and microbiota-derived compounds) in fecal samples Enable simultaneous analysis of a large array of cytokines, chemokines, and metabolites in small sample volumes Interface with Thermo Fisher Scientific Luminex platforms for downstream immune/metabolic biomarker analysis Provide comprehensive untargeted metabolite coverage validated for use with human fecal samples. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-CC-OLAO-26-008751) by 12:00 PM eastern standard time on 08/31/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
Who won similar work
10 award notices on SAM.gov in the last 24 months. Match: Same agency (National Institutes of Health), same NAICS 541380.
| Winner | Awards | Value | Last |
|---|---|---|---|
| AZENTA US INC | 1 | $35.0M | Dec 2, 2024 |
| NORGEN BIOTEK CORP | 1 | $157K | Sep 19, 2025 |
| CDI LABORATORIES INC | 1 | $50K | Mar 17, 2025 |
| HISTOSERV, INC | 1 | $29K | May 5, 2025 |
| NEW YORK GENOME CENTER, INC. | 1 | – + 1 shared | Jan 10, 2025 |
| SEQMATIC, LLC | 1 | – + 1 shared | Jan 8, 2025 |
| UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ADMINISTRATIVE OFFICE BUILDING, SUITE 2200 104 AIRPORT DRIVE, SUITE 2200, CB 1350 Chapel Hill NC 27599 USA | 1 | – + 1 shared | Jan 10, 2025 |
| UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S FLOWER STREET FL 3 Los Angeles CA 90089 USA | 1 | – + 1 shared | Jan 10, 2025 |
| Washington University, The CAMPUS BOX 1054 ONE BROOKINGS DRIVE SAINT LOUIS MO 63130 USA | 1 | – + 1 shared | Jan 8, 2025 |
| INFINITY BIOLOGIX LLC | 1 | – + 1 shared | Jan 8, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in.
- Sep 19, 2025NORGEN BIOTEK CORP$157KQ--Small RNA characterization of urinary exosomes
- May 5, 2025HISTOSERV, INC$29KSignatures of aging outcomes
- Mar 17, 2025CDI LABORATORIES INC$50KCDI Laboratories HuProt v4.0 Human Proteome Microarrays with Biospecimen Screening Service and Analysis
- Jan 10, 2025NEW YORK GENOME CENTER, INC.$150.0M (shared ceiling)B--NCI IDIQ Contract Genomic Characterization Center
- Jan 10, 2025UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ADMINISTRATIVE OFFICE BUILDING, SUITE 2200 104 AIRPORT DRIVE, SUITE 2200, CB 1350 Chapel Hill NC 27599 USA$150.0M (shared ceiling)B--NCI IDIQ Contract Genomic Characterization Center
- Jan 10, 2025UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S FLOWER STREET FL 3 Los Angeles CA 90089 USA$150.0M (shared ceiling)B--NCI IDIQ Contract Genomic Characterization Center
- Jan 8, 2025INFINITY BIOLOGIX LLC$150.0M (shared ceiling)B--NCI IDIQ Contract Genomic Characterization Center
- Jan 8, 2025Washington University, The CAMPUS BOX 1054 ONE BROOKINGS DRIVE SAINT LOUIS MO 63130 USA$150.0M (shared ceiling)B--NCI IDIQ Contract Genomic Characterization Center
- Jan 8, 2025SEQMATIC, LLC$150.0M (shared ceiling)B--NCI IDIQ Contract Genomic Characterization Center
- Dec 2, 2024AZENTA US INC$35.0MQ--Childhood Cancer Data Initiative (CCDI)
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.